CTLA-4 primarily regulates T cell activation by competing with CD28 for ligand binding during the early priming phase, whereas PD-1 mainly functions in peripheral tissues by limiting T cell activity and promoting T cell exhaustion in advanced HCC. Here, CTLA4 is linked to hepatocellular carcinoma.